Angiotech Pharmaceuticals
 | This article has multiple issues. Please help improve it or discuss these issues on the talk page. (Learn how and when to remove these template messages)
|
| Company type | Public |
|---|---|
| Industry | Pharmaceutical |
| Founded | 1992  |
| Headquarters | , |
Key people | K. Thomas Bailey |
Number of employees | 1450[1] |
| Website | www.angiotech.com |
Angiotech is a pharmaceutical company in Vancouver, British Columbia, Canada. Its products enhance the performance of medical devices and biomaterials through the use of pharmacotherapeutics. Angiotech is a global specialty pharmaceutical and medical device company that discovers, develops, and markets innovative technologies and medical products primarily for local diseases or for complications associated with medical device implants, surgical interventions and acute injury.
In April 2010, Angiotech acquired Haemacure manufacturing to develop human biological adhesives, hemostats and therapeutic proteins.
Angiotech, based in Vancouver, British Columbia, was founded in 1992 by William L. Hunter, M.D., Lindsay Machan, M.D., and Larry Arsenault, Ph.D.
In 2017, Angiotech was acquired by a consortium led by the U.S. healthcare investment firm Vivo Capital and China's ZQ Capital. [2]
References
- ^ "Company Profile for Angiotech Pharmaceuticals Inc (CA;ANP)". Archived from the original on 2012-02-29. Retrieved 2008-10-10.
- ^ Falconer, Kirk (2016-12-19). "Angiotech Pharmaceuticals to be acquired by Vivo, ZQ-led group". PE Hub. Retrieved 2019-10-28.
{{cite web}}: CS1 maint: url-status (link)
External links
 | This article about a medical, pharmaceutical or biotechnological corporation or company is a stub. You can help Wikipedia by expanding it. |
 | This article about a Canadian corporation or company is a stub. You can help Wikipedia by expanding it. |